Featured Research

from universities, journals, and other organizations

Immune response to heart attack worsens atherosclerosis, increases future risk

Date:
June 27, 2012
Source:
Massachusetts General Hospital
Summary:
A heart attack doesn't just damage heart muscle tissue by cutting off its blood supply, it also sets off an inflammatory cascade that worsens underlying atherosclerosis, actively increasing the risk for a future heart attack. These findings suggest an important new therapeutic strategy for preventing heart attacks and strokes, both of which are caused when atherosclerotic plaques rupture and block important blood vessels.

A heart attack doesn't just damage heart muscle tissue by cutting off its blood supply, it also sets off an inflammatory cascade that worsens underlying atherosclerosis, actively increasing the risk for a future heart attack. These findings from a study receiving advance online publication in Nature suggest an important new therapeutic strategy for preventing heart attacks and strokes, both of which are caused when atherosclerotic plaques rupture and block important blood vessels.

"We have known for a long time that heart attack patients are at increased risk for a second heart attack or a stroke, and now we know why," says Matthias Nahrendorf, MD, PhD, of the MGH Center for Systems Biology, senior author of the report from a team of researchers from the USA, Canada, Germany and the Netherlands. "The immune response to the infarct -- tissue damaged by lack of oxygen -- can accelerate the underlying disease by actually increasing the size and inflammation of the atherosclerotic plaque."

The study was designed to test the hypothesis that systemic inflammation caused by heart muscle damage would worsen pre-existing atherosclerosis. Using a mouse model genetically programmed to develop atherosclerosis, the researchers conducted a series of experiments showing that experimentally induced heart attacks led to the following:

• increased activity, in atherosclerotic plaques at a distance from the induced heart attack, of enzymes that break down the fibrous plaque cap, possibly leading to future rupture,

• accumulation of monocytes and other inflammatory immune cells in those atherosclerotic plaques,

• increased generation in the spleen of monocyte progenitors, along with changes in the function of those immune cells,

• increased release from the bone marrow of blood stem cells, which traveled to the spleen, triggered by increased activation of the sympathetic nervous system.

"The ancient fight-or-flight responses to injury stimulate immune cell activities that are involved in wound healing. But when the 'wound' is in the heart and caused by atherosclerosis, that increased activity actually accelerates the underlying disease," Nahrendorf explains. "While most of this work was done in mice, we have hints that something similar may happen in human patients -- for example, we found increased numbers of blood stem cells in the spleens of patients who had died shortly after a heart attack. "

Ralph Weissleder, MD, PhD, a corresponding author of this study and director of the MGH Center for Systems Biology where the work was performed, adds that these findings set the stage for a totally novel approach to cardiovascular disease. Therapies directed to the sites of white blood cell production, including the bone marrow or the spleen, may be able to prevent immune-system exacerbation of atherosclerosis. "This gives us potential new therapeutic targets that we had not thought about before. Clinically, we focus on reducing risk factors such as elevated cholesterol and blood pressure, but not inflammation. We hope our work can help change that," he says.

Weissleder is a professor of Radiology, and Nahrendorf an assistant professor of Radiology at Harvard Medical School. Co-lead authors of the Nature paper are Partha Dutta, PhD, and Gabriel Courties, PhD, of the MGH Center for Systems Biology. Collaborators include Filip Swirski, PhD, MGH Center for Systems Biology, and Peter Libby, MD, chief of Cardiology at Brigham and Women's Hospital, where the clinical data were analyzed. The study was primarily supported by grants from the National Institutes of Health.


Story Source:

The above story is based on materials provided by Massachusetts General Hospital. Note: Materials may be edited for content and length.


Journal Reference:

  1. Partha Dutta, Gabriel Courties, Ying Wei, Florian Leuschner, Rostic Gorbatov, Clinton S. Robbins, Yoshiko Iwamoto, Brian Thompson, Alicia L. Carlson, Timo Heidt, Maulik D. Majmudar, Felix Lasitschka, Martin Etzrodt, Peter Waterman, Michael T. Waring, Adam T. Chicoine, Anja M. van der Laan, Hans W. M. Niessen, Jan J. Piek, Barry B. Rubin, Jagdish Butany, James R. Stone, Hugo A. Katus, Sabina A. Murphy, David A. Morrow, Marc S. Sabatine, Claudio Vinegoni, Michael A. Moskowitz, Mikael J. Pittet, Peter Libby, Charles P. Lin, Filip K. Swirski, Ralph Weissleder, Matthias Nahrendorf. Myocardial infarction accelerates atherosclerosis. Nature, 2012; DOI: 10.1038/nature11260

Cite This Page:

Massachusetts General Hospital. "Immune response to heart attack worsens atherosclerosis, increases future risk." ScienceDaily. ScienceDaily, 27 June 2012. <www.sciencedaily.com/releases/2012/06/120627132057.htm>.
Massachusetts General Hospital. (2012, June 27). Immune response to heart attack worsens atherosclerosis, increases future risk. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2012/06/120627132057.htm
Massachusetts General Hospital. "Immune response to heart attack worsens atherosclerosis, increases future risk." ScienceDaily. www.sciencedaily.com/releases/2012/06/120627132057.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins